source
- Novo Nordisk aims to bring triple-G obesity injection to market by 2030Novo Nordisk said it plans to launch a triple‑G obesity injection by 2030. The drug would combine agonist activity at the GLP‑1, GIP and glucagon receptors, a class that researchers believe could b…
- Endpoints News identifies 25 biopharma CEOs earning $25M or more in 2025Endpoints News released a ranking of the highest-paid chief executives in the biopharma sector for 2025. For the first time in four years the publication raised the minimum compensation threshold…